Purpose of review Myeloproliferative neoplasms (MPN) are conditions of great interest because of the identification of their molecular basis and of the entering of new small molecules into clinical practice. The aim of this review is to report the role of mutations in the diagnosis, prognosis, and in the prediction of response to JAK inhibitors in MPN. Recent findings New mutations of the CALR gene have been discovered in patients without JAK2 or MPL mutations and are now included in the World Health Organization classification system. The role of ASXL1 and SRSF2 together with the driver mutations is emerging in the prognostication of myelofibrosis. Summary A wide mutational analysis of MPN helps to define diagnosis and prognosis. In the future, clinical trials based on a robust valuation of mutations will guide treatment decision-making towards precision medicine. © 2016 Wolters Kluwer Health, Inc.

New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms

PASSAMONTI, FRANCESCO
Primo
Writing – Original Draft Preparation
;
Mora, B.
Secondo
Writing – Original Draft Preparation
;
2016-01-01

Abstract

Purpose of review Myeloproliferative neoplasms (MPN) are conditions of great interest because of the identification of their molecular basis and of the entering of new small molecules into clinical practice. The aim of this review is to report the role of mutations in the diagnosis, prognosis, and in the prediction of response to JAK inhibitors in MPN. Recent findings New mutations of the CALR gene have been discovered in patients without JAK2 or MPL mutations and are now included in the World Health Organization classification system. The role of ASXL1 and SRSF2 together with the driver mutations is emerging in the prognostication of myelofibrosis. Summary A wide mutational analysis of MPN helps to define diagnosis and prognosis. In the future, clinical trials based on a robust valuation of mutations will guide treatment decision-making towards precision medicine. © 2016 Wolters Kluwer Health, Inc.
2016
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84957432341&partnerID=40&md5=75a719c0acf4d831aa4c40391dc43723
fedratinib; imetelstat; interferon; momelotinib; ruxolitinib; telomerase, allogeneic stem cell transplantation; cancer prognosis; drug response; enzyme activity; enzyme inhibition; gene mutation; genotype phenotype correlation; human; molecular diagnosis; molecular genetics; molecular model; mutational analysis; myeloid metaplasia; myeloproliferative neoplasm; nonhuman; prediction; priority journal; Review; tumor diagnosis; CALR; JAK2; myelofibrosis; polycythemia; thrombocythemia; transplant
Passamonti, Francesco; Mora, B.; Maffioli, M.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2046345
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 18
social impact